(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 March 2003 (20.03.2003)

PCT

(10) International Publication Number
WO 03/022864 A1

(51) International Patent Classification[7]: C07J 1/00, A61K 31/565, A61P 5/26

(21) International Application Number: PCT/EP02/10041

(22) International Filing Date:
6 September 2002 (06.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01203455.9 12 September 2001 (12.09.2001) EP

(71) Applicant *(for all designated States except US)*: **AKZO NOBEL N.V.** [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **VAN DER LOUW, Jaap** [NL/NL]; NV Organon, PO Box 20, NL-5340 BH Oss (NL). **LEYSEN, Dirk** [BE/NL]; NV Organon, PO Box 20, NL-5340 BH Oss (NL). **DE GOOIJER, Marcel, Evert** [NL/NL]; NV Organon, PO Box 20, NL-5340 BH Oss (NL).

(74) Agent: **KRAAK, H.**; P.O. Box 20, NL-5340 BH Oss (NL).

(81) Designated States *(national)*: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, RO, RU, SG, SI, TT, UA, US, UZ, VN, YU, ZA.


(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/022864 A1

(54) Title: 17ALPHA-HYDROXY-14BETA-STEROIDS WITH HORMONAL EFFECT



(I)

(57) Abstract: This invention relates to steroidal compounds having the formula (I), wherein: R^1 is O, (H,H), (H,OH), NOH, whereby OH is optionally etherified or esterified; R^2 and R^3 are independently hydrogen or (C_{1-4}) alkyl and at least one of R^2 and R^3 is (C_{1-4}) alkyl; R^4 is hydrogen, or (C_{1-15}) acyl for use in androgen-related treatments, such as androgen insufficiency and male or female contraception.